Novo Nordisk scores a win for semaglutide in obesity, potentially setting up a next-gen battle with Eli Lilly

Novo Nordisk pulled a highly anticipated win for its GLP-1 therapy semaglutide in obesity on Friday, becoming the first company to get a chronic weight management drug for adults past regulators since 2014.

Semaglutide — marketed for Type 2 diabetes as Ozempic — was first approved in 2017. The blockbuster...

Click to view original post